Jupiter Neurosciences Launches Nugevia™ Longevity Supplement Line to Drive Revenue While Developing CNS Treatments
Jupiter Neurosciences Inc. has launched its Nugevia™ direct-to-consumer longevity supplement line, leveraging its patented JOTROL™ resveratrol formulation to generate immediate revenue while continuing pharmaceutical development for central nervous system disorders.
Jupiter Neurosciences Inc. (NASDAQ: JUNS) has launched Nugevia™, its direct-to-consumer longevity product line, marking a significant strategic move to generate revenue while continuing its clinical-stage pharmaceutical development. The launch represents a two-pronged business approach that reduces the company's dependency on the slower clinical process, where drugs can take years to reach the market.
The Nugevia line leverages JOTROL™, the company's enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects. This formulation is backed by more than eight years of pharmaceutical development and is designed to deliver therapeutically relevant, safe levels of resveratrol. Beyond its antioxidant properties, resveratrol activates PARP-1, an important protein in DNA repair and stress response, while also improving cardiovascular health, enhancing cognitive function, and providing antibacterial and antiviral benefits against food-borne pathogens.
The scientifically backed longevity market represents a substantial opportunity, valued at $65 billion in 2023 and projected to reach $314 billion by 2030. Jupiter Neurosciences estimates the combined addressable market for mind, beauty, and energy products at approximately $8 trillion, positioning Nugevia to capitalize on growing global demand for products that extend both lifespan and healthspan.
The initial three Nugevia formulations target specific areas of consumer interest within the longevity space. Nugevia GLO is designed as a daily supplement to support radiant, resilient skin from the inside out by promoting cellular defense, collagen integrity, and hydration. Nugevia PWR focuses on mitochondrial health, formulated to support cellular energy, endurance, and recovery. Nugevia MND targets cognitive function protection and enhancement, supporting overall brain health. All three products will be available directly to consumers this fall through the company's DTC model.
What sets Nugevia apart from single-ingredient supplements, according to the company, is its precision-engineered "intelligent stacking" of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. This approach builds on the same proprietary technology platform that underpins the company's prescription drug development.
Christer Rosen, Chairman and CEO of Jupiter Neurosciences, emphasized the personal significance of the cognitive health product, noting that his mother passed away from Alzheimer's Disease and the company's former CFO ultimately lost his fight to Parkinson's Disease. "This is personal, this is important and based on our JOTROL pharmaceutical pre-clinical and clinical data we are here to bring what we believe is the best cognition product to the market," Rosen stated.
To build brand awareness, Jupiter Neurosciences has named professional golfer Annika Sörenstam as its first brand ambassador. Sörenstam, who has won over 95 international tournaments including 72 LPGA titles and 10 major championships, will work with the company to promote Nugevia and the science behind the product line. Rosen described Sörenstam as "a powerful advocate for our mission to support healthy aging and optimal function at any stage of life" given her long career maintaining competitive performance.
The launch of Nugevia represents a strategic shift for clinical-stage pharmaceutical companies, traditionally dependent on years of development before realizing revenue. By leveraging its JOTROL technology for immediate consumer products while continuing drug development for central nervous system disorders and rare diseases, Jupiter Neurosciences aims to create a sustainable revenue stream that supports its broader pharmaceutical ambitions.